| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED NOVEMBER 2017. Refer to TA795: Ibrutinib for treating Waldenstrom's macroglobulinaemia (CDF Review of TA491) for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | ibrutinib (Imbruvica®) | |
| Formulation | 140 mg hard capsule | |
| Reference number | 2215 | |
| Indication | Treatment of adult patients with Waldenstrom's macroglobulinemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 17/11/2015 | |
| Date of issue | 18/11/2015 | |
| NICE guidance | TA795: Ibrutinib for treating Waldenstrom's macroglobulinaemia (CDF Review of TA491) |
|